Elan cuts jobs and pulls out of biologics manufacturing
This article was originally published in Scrip
Executive Summary
Elan is to lay off 230 staff and postpone investment in a biologics manufacturing facility for bapineuzumab, an investigational Alzheimer's drug being developed with Wyeth.